Sound Pharmaceuticals (SPI) has filed an investigative new drug (IND) application with the United States Food and Drug Administration (FDA) for their investigative oral agent SPI-3005 (ebselen). The IND is for use of SPI-3005 for the prevention of hearing loss (ototoxicity) induced by chemotherapy.
SPI-3005 has been designed to attenuate platinum or taxane-based chemotherapy ototoxicity without interfering with their effectiveness.
SPI-3005 will be tested in clinical trials including patients with advanced lung and head and neck cancer patients being treated with platinum-based chemotherapy.
Fyarro for Malignant Perivascular Epithelioid Cell Tumor (PEComa)
The U.S. Food and Drug Administration (FDA) has approved FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Radiofrequency Ablation Effective For Small Kidney Cancers
Radiofrequency ablation an an effective treatment for patients with small kidney cancers.